Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Background Immune-modulating antibodies targeting programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have demonstrated promising antitumor efficacy in various types of cancers, especially highly mutated ones. Genetic alterations in DNA damage response and repair (DDR) genes can l...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Jae Ho Byun, Jeeyun Lee, Kyong Hwa Park, Eun Joo Kang, Sang Joon Shin, In Gyu Hwang, Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Jason K Sa, Sook Ryun Park, Jung Sun Kim, Yu Jung Kim, Woo Kyun Bae, Won Jin Chang, Eun-Ok Kim
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Online Access:	https://jitc.bmj.com/content/12/3/e008638.full